Skyrizi Side Effects

Generic name: risankizumab

Medically reviewed by Philip Thornton, DipPharm. Last updated on Jan 10, 2025.

Note: This document provides detailed information about Skyrizi.

Applies to risankizumab: parenteral injection for iv infusion, parenteral injection for sub-q use Side Effects associated with risankizumab. Some dosage forms listed on this page may not apply specifically to the brand name Skyrizi.

Applies to risankizumab: parenteral injection for iv infusion, parenteral injection for sub-q use.

Side effects include:

Adverse reactions (≥1%) in patients with plaque psoriasis and psoriatic arthritis: upper respiratory infection, headache, fatigue, injection site reaction, tinea infection.

Adverse reactions (>3%) in patients receiving induction treatment for Crohn disease: upper respiratory infection, headache, arthralgia.

Adverse reactions (>3%) in patients receiving maintenance treatment for Crohn disease: arthralgia, injection site reaction, abdominal pain, anemia, pyrexia, back pain, arthropathy, urinary tract infection.

Adverse reactions (≥3%) in patients receiving induction treatment for ulcerative colitis: arthralgia.

Adverse reactions (≥3%) in patients receiving maintenance treatment for ulcerative colitis: arthralgia, pyrexia, injection site reactions, rash.

For healthcare professionals

Applies to risankizumab: intravenous solution, subcutaneous kit, subcutaneous solution.

Gastrointestinal adverse events

• Common (1% to 10%): Abdominal pain^[Ref]

Dermatologic

• Common (1% to 10%): Tinea infections (e.g., tinea pedis, tinea cruris, body tinea, tinea versicolor, tinea manuum, tinea infection)
• Uncommon (0.1% to 1%): Folliculitis, urticaria

Postmarketing: Eczema, rash^[Ref]

Hematologic

• Common (1% to 10%): Anemia^[Ref]

Hypersensitivity

• Common (1% to 10%): Hypersensitivity reactions^[Ref]

Hypersensitivity

Immunologic

• Very common (10% or more): Immunogenicity (24%), infections (e.g., cellulitis, osteomyelitis, sepsis, herpes zoster) (22%)^[Ref]

Local

• Common (1% to 10%): Injection site reactions (e.g., bruising, erythema, extravasation, hematoma, hemorrhage, infection, inflammation, irritation, pain, pruritus, reaction, swelling, warmth)^[Ref]

Musculoskeletal

• Common (1% to 10%): Arthralgia, arthropathy, back pain^[Ref]

Nervous system

• Common (1% to 10%): Headache (e.g., tension headache, sinus headache, cervicogenic headache)^[Ref]

Other

• Common (1% to 10%): Fatigue, asthenia, pyrexia^[Ref]

Respiratory

• Very common (10% or more): Upper respiratory infections (e.g., respiratory tract infection [viral, bacterial, unspecified], sinusitis [including acute], rhinitis, nasopharyngitis, pharyngitis [including viral], tonsillitis) (up to 13%)^[Ref]

See also:

Frequently asked questions

• What are monoclonal antibodies?
• What's the dosing schedule for Skyrizi?
• Does Skyrizi cause cancer?
• Can you drink alcohol while taking Skyrizi?
• Skyrizi vs Humira for plaque psoriasis - How do they compare?
• Who makes Skyrizi and where is it made?
• Does Skyrizi cause hair loss?
• Is Skyrizi approved for treating psoriatic arthritis?
• Skyrizi vs Ilumya. What’s the difference?

Further information

Skyrizi side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.

Medical Disclaimer